

**OFFICIAL STUDY TITLE: PALLIATIVE CARE AND LEGAL ASPECTS OF TREATMENT LIMITATION DECISIONS IN ICU: A SURVEY OF CLINICIANS' PERCEPTIONS**

**PROTOCOL SUBMITTED FOR IRB APPROVAL: Scientific Council, Ethics and Deontology Committee of Evangelismos General Hospital, Athens, Greece; Protocol Submission Date: December 15, 2023; Protocol Approval Date: December 19, 2023 (14<sup>th</sup> Regular Session of the Committee); Protocol ID/Approval No.: 606-20/12/23.**

## **SURVEY ON PALLIATIVE CARE AND LAW PERCEPTION**

**Investigators:** Spyros D. Mentzelopoulos, MD, PhD, DEAA, EDIC (Professor of Intensive Care Medicine, NKUA) [Principal Investigator], Victoria Metaxa, MD, PhD (Consultant in Intensive Care Medicine, King's College NHS trust, London) [Principal Investigator], Hanne Irene Jensen, PhD, CCN (Professor, Lillebaelt hospital, University of Southern Denmark), Christiane Hartog, MD, PhD (Professor of Intensive Care Medicine, CHARITE University Berlin) [Project Coordinator].

## **INTRODUCTION**

In countries with patient/family autonomy-oriented end-of-life (EOL) legislation (1-8), published data indicate variation of healthcare professionals' awareness of the specific legal provisions and/or regulations enabling limitation of life-sustaining treatments (4, 5, 8). Furthermore, communication difficulties and/or uncertainties about the validity of previously recorded patient preferences (e.g. in the form of advance directives) may result in heterogenous application of pertinent EOL laws/regulations (9-12). This may include cases of poor compliance with, or even opposition to new laws (10, 12).

The absence of accurate and in-depth EOL legal knowledge of clinicians (4) may be associated with perceptions that applicable laws/regulations are either too restrictive (10) or excessively "liberal" for the patient (12). Furthermore, critical care physicians and/or nurses may lack specific knowledge about palliative care (13, 14). Accordingly, physicians/nurses may also not be aware of the palliative nature of their everyday practice or have a clear understanding of primary and specialist palliative care.

Given the above-mentioned knowledge gaps of healthcare professionals caring for critically ill patients, we propose to conduct a Europewide, descriptive survey for intensive care unit (ICU) clinicians, primarily aimed at addressing the following questions: 1) "How much of ICU everyday practice is palliative care and how is it practiced?"; and 2) "How do clinicians perceive the medico-legal framework around therapy limitations, patient autonomy and prognostication discussions with patients and families?" In addition, this survey will enable us to comparatively assess the perceived extent of ICU palliative care practice in the presence vs. absence of EOL legislation.

## **METHODS**

### **Study participants and protocol approval**

The target population of this descriptive, open survey will include ICU physicians and nurses working in at least 100 ICUs across at least 20 European countries. Each one of participating ICUs will be represented by one or more healthcare

professionals, and the target convenience-sample size will amount to at least 500 respondents (see also below-provided statistical analysis plan). This survey study is part of the European Union-funded Enhancing Palliative Care in ICU (EPIC) project (Proposal number: 101137221; HORIZON-HLTH-2023-DISEASE-03-01). The study protocol will be submitted for approval to the Scientific Council of Evangelismos Hospital, Athens, Greece.

### **Informed consent and data protection**

A similar methodology has been recently described (15). According to the Helsinki declaration, participation in research requires informed consent of the participant. According to Regulation 679/2016 {or General Data Protection regulation (GDPR) of the European Parliament and of the Council, "consent" of the data subject means any freely given, specific, informed and unambiguous indication of the data subject's wishes by which he or she, by a statement or by a clear affirmative action, signifies agreement to the processing of personal data relating to him or her."

Participation in and completion of the current survey means that the participant accepts to share their knowledge on palliative care practice, EOL legislation and EOL practice in their country. The estimated time for survey completion is between 30 and 60 min.

The procedure for "*pseudonymisation*" is detailed below.

A set of 20 consecutive random numbers (range, 10-29) will be generated using "Research Randomizer ([www.randomizer.org](http://www.randomizer.org))". Each one of the aforementioned numbers will be assigned to a European country (country code) drawn according to alphabetic order from the list of participating countries. Next to the 2 digits of the country code, a one-to-three-digit number will be placed to represent each participant's temporal order of participation relative to other participants from the same country. The country-specific, temporal order of participants will be determined according to the exact time of submission of the completed study questionnaire. This will form the personal, three-to-five digit code for each study participant.

The survey database will be hosted by the CHARITE Berlin Simulation and Training Centre. Data on questionnaire domains will be stored next to the participant's personal code in Microsoft Excel format. This electronic Masterfile will be stored onto the password-protected hard disk of a personal computer. In addition, next to the participant's personal code, we will enter the following personal data 1) age; 2) gender; 3) religion; 4 and 5) country and center/city of professional activity; 6) characteristics of the participant's ICU (e.g. general, medical, surgical, etc.); 7) the participant's professional focus (e.g. clinical, research, etc.); and 8 and 9) the participant's professional grade (e.g. consultant, professor, etc.) and ICU experience (in years of work). There will be no collection/recording of participants' names or electronic mail addresses. Therefore, the Masterfile will fulfill the criterion of "*pseudonymization*."

## **Development and testing of the questionnaire**

The final version of the questionnaire is presented in the Appendix of the current protocol. The questionnaire was developed based on published, relevant literature (16-23), investigator consensus and comments collected by preliminary testing; the latter comprised administration of the questionnaire to a total of 30 Danish, British and Greek ICU clinicians (10 from each country). Danish and British clinicians were asked to qualitatively assess the readability and understandability of the survey questions and provide comments for improvement as regards content and clarity. Greek clinicians were asked to first respond to the questionnaire, in order to obtain an estimate of the actual time required for survey completion, and subsequently also provide their comments on content and clarity.

In its finalized form, the survey consists of an introduction and 4 sections. The introduction includes core definitions concerning advance directives and shared decision making (16), palliative care (<https://www.who.int/europe/news-room/fact-sheets/item/palliative-care>), treatment limitation (17), active shortening of the dying process (or euthanasia) (17), and family (18). The first section aims at collecting data on participant characteristics, including age, gender, religion, location of professional activity (including hospital name), professional focus, grade and experience. The second section includes questions on patient-level, family-level and healthcare-level domains of palliative care (19-21), as well as participant-rating (5-point scale) of the importance of domain elements; these elements pertain to physical and psychosocial aspects of care, communication, family support and system-level support (19-21). The third section includes questions (and rating by 5-point scale wherever appropriate) about EOL legislation and practices such as applicability of and clinician-compliance with advance directives, treatment limitation (i.e. withholding or withdrawing of life-sustaining treatments), euthanasia, terminal analgesia/sedation, EOL decision-making and family presence during cardiopulmonary resuscitation (17, 21). Lastly, the fourth section includes 12 questions with two-choice answers (i.e. yes/no) in the context of a recently introduced EOL practice score (17, 22) (with definitions of score subcomponents appended), and an additional 3 general questions about palliative care practice in the participant's ICU.

## **Website, survey promotion and access to the questionnaire**

The electronic version of the questionnaire will be set up at a dedicated website using LimeSurvey. Invitation links for this mandatory survey (meaning: all website visitors are expected to fill the survey) will be sent Europe-wide by EPIC partner European Society of Anaesthesiology and Intensive Care (ESAIC) with the use of social media and email channels; ESAIC has approximately 18.000 followers. Additional invitation links will be emailed by the investigators to their networks of research associates; the latter will also be encouraged to share the invitation links with their own networks of colleagues/associates.

## **Additional protocol features**

There are no planned incentives for participants. Data collection will be performed once from each participating center, within January 1st to July 30, 2024.

The questionnaire will be administered over a total of 22 electronic pages. The items (i.e. subsection questions) per page will range from 1 (open-ended questions) to 9 (multiple-choice questions). Options for responses such as "do not know" or "not applicable" are provided for all questions of sections 2 and 3 and question 25.1 of section 4. In addition, adaptive questioning (i.e. "do not know" or "not applicable" responses to the first question of a subsection triggering cancellation of all subsequent questions of that particular subsection) is used from question 15.1 through question 21.1 of section 3; this is aimed at reducing the number of questions in cases of 1) lack of participants' knowledge about whether certain EOL practices are legally allowed; or 2) participant awareness of absence of any preceding/current, local legalization of an EOL practice. In section 4, EOL practice score questions have by original protocol only 2 possible answers (17, 23), whereas questions 25.2, 25.3 and 25.4 are open ended.

The completeness of participants' responsiveness (i.e. "all survey questions answered") will be checked before questionnaire submission, and participants will be prompted through a "pop-up" dialog box to provide any missing responses, or indicate that they do not wish to respond to a specific question. Furthermore, just prior to questionnaire submission, another "pop-up" dialog box will display a pre-submission prompt to review (and revise if needed) the originally provided responses.

Internet protocol (IP) address data will be used to ensure the uniqueness of survey participants. More specifically, unlimited, repetitive access to the questionnaire will be allowed from an IP address of a client computer until survey submission. However, following submission of the filled questionnaire through an IP address, will result in discontinuation of survey accessibility through that particular IP address.

Due to the use of snowballing dissemination and sharing of invitation links, it will not be possible to calculate the survey response rate. However, survey completion rate will actually be calculated by dividing the total number of submitted questionnaires to the number of first-survey page visitors. Furthermore, questionnaire completeness rate will be calculated by dividing the number of questionnaires without any missing response to the total number of submitted questionnaires. Missing responses will correspond to questions to which participants will have indicated that they do not wish to answer (see also above). Mutually contradictory responses from participants originating from the same study center, or the same city, or the same country constitute a possibility, especially for the third and fourth section of the survey (15, 17, 22-24). For example, two or more

participants from the same center/city/country may respond differently as regards the legal bindingness of advance directives. In such cases, mutually contradictory responses will be used to estimate the extent of country-specific variation in the perception of law and/or local palliative care practice.

## **Study outcomes**

The primary outcomes will be the absolute numbers of positive (i.e. yes) responses to question groups 10 through 14 of survey section 2, 15 through 23 of section 3, and 24 and 25 of section 4.

Secondary outcomes will include 1) the absolute numbers of positive (i.e. yes) responses to question groups 10 through 14 of section 2 in the presence vs. absence of a positive response to question 24.12 of section 4.

## **Statistical analysis plan**

Statistical analyses will include 1) descriptive statistics; 2) assessment of distribution normality (by Kolmogorov Smirnov test); 3) assessment of European country-/region-level heterogeneity in the responses; and 4) region-level comparisons of responses (17).

We expect to determine substantial heterogeneity in the responses, primarily between northern and southern Europe and central and southern Europe, and generally between countries with high vs low palliative care service integration.

High palliative care score will be defined as presence of at least 16 positive responses (out of 24 possible positive responses) to question groups 10 through 14 of survey section 2.

Generalized estimating equations (GEE) models with robust SEs and exchangeable working correlation structure accounting for the factor center (24) will be applied to examine associations between a high palliative care score, the 9 clinician demographic variables of survey section 1 [with "country" stratified according to "northern, central or southern European region" (17,23,24)], and the EOL practice score and/or its subcomponent EOL practice variables listed in question group 24 of survey section 4. The dependent variable in this analysis will be high palliative care score, yes or no. Reference category for region will be "southern Europe" (17). The maximum number of GEE explanatory variables will be 21. Consequently, our target sample size of 500 participants is expected to result in approximately 24 observations (i.e. response data-points) per variable; this exceeds the recommended threshold of 20 observations per variable (17,23,24,25) by 20% and establishes an adequate safety margin, aimed at addressing the possibility of missing responses.

Significance will be set at two-sided  $P < 0.05$ . Analyses will be conducted using the latest versions of SPSS or R software.

### **Expected general benefits from the current study**

Survey results will likely serve to refine the EPIC harmonized practice model of palliative care, further clarifying the concepts of primary versus specialist palliative care and ICU clinicians' role in the practice concept. Results from the survey on legal issues are expected to inform stakeholders involved in policy and legislation, and improve security for ICU clinicians in the respective countries and Europe-wide.

### **Expected benefits for the conduct of the EPIC trial**

A factsheet on legal issues will be developed as tool for the EPIC intervention. Accordingly, work collecting information on the legal ambiguity around therapy limiting decisions in participating countries is already underway. This information will be incorporated into factsheets on legal aspects tailored to each country participating in EPIC, based on published evidence and expert opinion from the respective national centers. The factsheets are expected to achieve 1) improved awareness about national laws and regulations on therapy limitations; 2) legal constraints or deficits regarding EOL care and 3) applicability of the law to palliative care in ICU. These factsheets will be handed out during the EPIC crossover period to every ICU clinician in participating ICUs.

## REFERENCES

1. Riessen R, Bantlin C, Wiesing U, Haap M. Therapiezieländerungen auf einer internistischen Intensivstation. Einfluss von Willensäußerungen der Patienten auf Therapieentscheidungen [End-of life decisions in intensive care units. Influence of patient wishes on therapeutic decision making]. *Med Klin Intensivmed Notfmed*. 2013;108:412-8.
2. Strauss S, Kuppinger D, Hartl WH. Versterben vor und nach dem „Patientenverfügungsgesetz“: Erfahrungen einer chirurgischen Intensivstation [Quality of dying processes after commencement of the German Living Will Act : Experiences of a surgical intensive care unit]. *Chirurg*. 2017;88:244-250.
3. Graw JA, Marsch F, Spies CD, Francis RCE. End-of-Life Decision-Making in Intensive Care Ten Years after a Law on Advance Directives in Germany. *Medicina (Kaunas)*. 2021;57:930.
4. Doron D, Wexler ID, Shabtai E, Corn BW. Israeli Dying Patient Act: physician knowledge and attitudes. *Am J Clin Oncol*. 2014;37:597-602.
5. Boulanger A, Chabal T, Fichaux M, Destandau M, La Piana JM, Auquier P, Baumstarck K, Salas S. Opinions about the new law on end-of-life issues in a sample of french patients receiving palliative care. *BMC Palliat Care*. 2017;16:7.
6. Ciliberti R, Gorini I, Gazzaniga V, De Stefano F, Gulino M. The Italian law on informed consent and advance directives: New rules of conduct for the autonomy of doctors and patients in end-of-life care. *J Crit Care*. 2018;48:178-182.
7. Bonsignore A, Bragazzi NL, Basile C, Pelosi P, Gratarola A, Bonatti G, Patroniti N, Ciliberti R. Development and Validation of a Questionnaire investigating the Knowledge, Attitudes and Practices of Healthcare Workers in the Field of Anesthesiology concerning the Italian Law on Advance Healthcare Directives: a Pilot Study. *Acta Biomed*. 2021;92:e2021092.
8. White B, Willmott L, Cartwright C, Parker MH, Williams G. Knowledge of the law about withholding or withdrawing life-sustaining treatment by intensivists and other specialists. *Crit Care Resusc*. 2016;18:109-115.
9. Le Dorze M, Kandelman S, Veber B; SFAR's Ethics Committee. End-of-life care in the French ICU: Impact of Claeys-Leonetti law on decision to withhold or withdraw life-supportive therapy. *Anaesth Crit Care Pain Med*. 2019;38:569-570.
10. Evans N, Bausewein C, Meñaca A, Andrew EV, Higginson IJ, Harding R, Pool R, Gysels M; project PRISMA. A critical review of advance directives in Germany: attitudes, use and healthcare professionals' compliance. *Patient Educ Couns*. 2012;87:277-88.



11. Mentzelopoulos SD, Slowther AM, Fritz Z, Sandroni C, Xanthos T, Callaway C, Perkins GD, Newgard C, Ischaki E, Greif R, Kompanje E, Bossaert L. Ethical challenges in resuscitation. *Intensive Care Med.* 2018;44:703-716.
12. Vitale C, de Nonneville A, Fichaux M, Salas S. Medical staff opposition to a deep and continuous palliative sedation request under Claeys-Leonetti law. *BMC Palliat Care.* 2019;18(1):2.
13. Mercadante S, Gregoretti C, Cortegiani A. Palliative care in intensive care units: why, where, what, who, when, how. *BMC Anesthesiol.* 2018;18:106.
14. Sesma-Mendaza A, Aranguren-Sesma M, Estraviz-Pardo F, Lizarazu-Armendáriz E, Goñi-Viguria R. Nurses' knowledge about palliative care in a critical care unit. *Enferm Intensiva (Engl Ed).* 2022;33:197-205.
15. Mentzelopoulos SD, Couper K, Raffay V, Djakow J, Bossaert L. Evolution of European Resuscitation and End-of-Life Practices from 2015 to 2019: A Survey-Based Comparative Evaluation. *J Clin Med.* 2022;11:4005.
16. Mentzelopoulos SD, Couper K, Voorde PV, Druwé P, Blom M, Perkins GD, Lulic I, Djakow J, Raffay V, Lilja G, Bossaert L. European Resuscitation Council Guidelines 2021: Ethics of resuscitation and end of life decisions. *Resuscitation.* 2021;161:408-432.
17. Sprung CL, Ricou B, Hartog CS, Maia P, Mentzelopoulos SD, Weiss M, Levin PD, Galarza L, de la Guardia V, Schefold JC, Baras M, Joynt GM, Bülow HH, Nakos G, Cerny V, Marsch S, Girbes AR, Ingels C, Miskolci O, Ledoux D, Mullick S, Bocci MG, Gjedsted J, Estébanez B, Nates JL, Lesieur O, Sreedharan R, Giannini AM, Fuciños LC, Danbury CM, Michalsen A, Soliman IW, Estella A, Avidan A. Changes in End-of-Life Practices in European Intensive Care Units From 1999 to 2016. *JAMA.* 2019 Nov 5;322(17):1692-1704. Erratum in: *JAMA.* 2019 5;322(17):1718.
18. Davidson JE, Aslakson RA, Long AC, Puntillo KA, Kross EK, Hart J, Cox CE, Wunsch H, Wickline MA, Nunnally ME, Netzer G, Kentish-Barnes N, Sprung CL, Hartog CS, Coombs M, Gerritsen RT, Hopkins RO, Franck LS, Skrobik Y, Kon AA, Scruth EA, Harvey MA, Lewis-Newby M, White DB, Swoboda SM, Cooke CR, Levy MM, Azoulay E, Curtis JR. Guidelines for Family-Centered Care in the Neonatal, Pediatric, and Adult ICU. *Crit Care Med.* 2017;45:103-128.
19. Virdun C, Luckett T, Lorenz K, Davidson PM, Phillips J. Dying in the hospital setting: A meta-synthesis identifying the elements of end-of-life care that patients and their families describe as being important. *Palliat Med.* 2017;31:587-601.
20. Leemans K, Deliëns L, Van den Block L, Vander Stichele R, Francke AL, Cohen J. Systematic Quality Monitoring For Specialized Palliative Care Services: Development of a Minimal Set of Quality Indicators for Palliative Care Study (QPAC). *Am J Hosp Palliat Care.* 2017;34(6):532-546.
21. Vuong C, Kittelson S, McCullough L, Yingwei Y, Hartjes T. Implementing primary palliative care best practices in critical care with the Care and Communication Bundle. *BMJ Open Qual.* 2019;8(3):e000513.

22. Mentzelopoulos SD, Bossaert L, Raffay V, Askitopoulou H, Perkins GD, Greif R, Haywood K, Van de Voorde P, Xanthos T. A survey of key opinion leaders on ethical resuscitation practices in 31 European Countries. *Resuscitation*. 2016;100:11-17.
23. Mentzelopoulos SD, Chen S, Nates JL, Kruser JM, Hartog C, Michalsen A, Efstathiou N, Joynt GM, Lobo S, Avidan A, Sprung CL; End-of-life Practice Score Study Group. Derivation and performance of an end-of-life practice score aimed at interpreting worldwide treatment-limiting decisions in the critically ill. *Crit Care*. 2022 13;26(1):106.
24. Avidan A, Sprung CL, Schefold JC, Ricou B, Hartog CS, Nates JL, Jaschinski U, Lobo SM, Joynt GM, Lesieur O, Weiss M, Antonelli M, Bülow HH, Bocci MG, Robertsen A, Anstey MH, Estébanez-Montiel B, Lautrette A, Gruber A, Estella A, Mullick S, Sreedharan R, Michalsen A, Feldman C, Tisljar K, Posch M, Ovu S, Tamowicz B, Demoule A, DeKeyser Ganz F, Pargger H, Noto A, Metnitz P, Zubek L, de la Guardia V, Danbury CM, Szűcs O, Protti A, Filipe M, Simpson SQ, Green C, Giannini AM, Soliman IW, Piras C, Caser EB, Hache-Marliere M, Mentzelopoulos SD; ETHICUS-2 Study Group. Variations in end-of-life practices in intensive care units worldwide (Ethicus-2): a prospective observational study. *Lancet Respir Med*. 2021;9:1101-1110.
25. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR.. A simulation study of the number of events per variable in logistic regression analysis. *J Clin Epidemiol*. 1996;49:1373-1379.

## APPENDIX. THE STUDY QUESTIONNAIRE

### **Palliative care and legal aspects of treatment limitation decisions in ICU A survey of clinicians' perceptions**

The primary objective of the current survey study is to obtain detailed information about European ICU clinicians' awareness of palliative care and relevant, local end-of-life (EoL) legislation.

Please note that by completing the following survey, you consent to participate in the study.

#### **Definitions**

Advance directive is an instrument that relays information concerning an individual's preferences and goals regarding medical procedures and treatments, especially those used for end-of-life care.

Advance care planning: A process that enables individuals to

- define goals and preferences for future medical treatment and care,
- thoroughly discuss these goals and preferences with family and health-care professionals
- record and review these preferences if appropriate.

The main objective of advance care planning is to help ensure that people receive medical care that is consistent with their values, goals and preferences during serious, chronic and/or acute/life-threatening illness.

Shared decision-making: shared decision-making is a collaborative process that allows patients, or their surrogates, and a possibly/preferably multidisciplinary team of healthcare professionals to reach consensus on which treatment strategies and interventions - including life-support limitation and palliative care- accord with the patient's values, goals, and preferences. [Adopted from Resuscitation. 2021;161:408-432].

Palliative care: is an approach that improves the quality of life of patients (adults and children) and their families who are facing problems associated with life-threatening illness. It prevents and relieves suffering through the early identification, correct assessment and treatment of pain and other problems, whether physical, psychosocial or spiritual (adopted from the WHO 2014 definition).

Treatment limitation/euthanasia: Treatment limitation in the form of withholding or withdrawing life-prolonging treatments should NOT be confused with euthanasia, which means active, intentional, and painless termination of a person's life by another person

acting at the request of the dying person.

Family: is defined by the patient or, in the case of minors or those without decision-making capacity, by their surrogates. In this context, the family may be related or unrelated to the patient. They are individuals who provide support and with whom the patient has a significant relationship.

## **Clinician Demographics**

### **1. Age**

(number)

### **2. Gender**

Male, Female, Other

### **3. Religion**

Buddhist, Catholic, Christian, Greek Orthodox, Hindu, Jewish, Muslim, Protestant, Other, None

### **4. Country of your professional activity**

Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Kosovo, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom, Other (please specify)

### **5. Name of hospital/healthcare facility and city of your professional activity**

(free text)

### **6. Characteristics of your intensive care unit (ICU)**

6.1 General/mixed, Medical, Surgical, Other

6.2 University-affiliated, Not University-affiliated

6.3 Number of ICU beds (number)

### **7. Your professional focus** (please choose all that apply)

Clinical, Education, Research, Management, Other (please specify)

### **8. Your grade** (please choose all that apply)

Nurse, Trainee / non-specialist, Consultant / specialist,

University-related (Lecturer/Professor), Other (please specify)

### **9. Your professional intensive care experience**

Less than 5 years, 5 to less than 10 years, 10 to 20 years, More than 20 years

## **Perceptions about provision of care for end of life / treatment limitation decisions**

**Please use the following 5-point scale to rate the level of importance (regarding routine/usual/standard practice) of the following domains of end-of-life patient care. Please note that the term "importance" corresponds to what the clinician considers as important for the care of ICU patients who are nearing end-of-life and have a documented poor prognosis.**

- 1=unimportant
- 2=low importance
- 3=average importance
- 4=high importance
- 5=maximum importance

**At the end of each domain, it is possible to clarify your responses and/or add other comments**

### **10. Physical aspects of care**

**10.1. The patient's pain is assessed at least once daily, depending on their individual needs**

**10.1.1. Is this part of your routine practice?** Yes, No, Don't know

**10.1.2. Importance rating.** 1,2,3,4,5

**10.2. Pain relief is part of the daily ward round goals**

**10.2.1. Is this part of your routine practice?** Yes, No, Don't know

**10.2.2. Importance rating.** 1,2,3,4,5

**10.3. The patient's breathing/dyspnea is assessed at least once daily, depending on their individual needs**

**10.3.1. Is this part of your routine practice?** Yes, No, Don't know

**10.3.2. Importance rating.** 1,2,3,4,5

**10.4. Relief of dyspnea is part of the daily ward round goals**

**10.4.1. Is this part of your routine practice?** Yes, No, Don't know

**10.4.2. Importance rating.** 1,2,3,4,5

**10.5. The patient's other symptoms are assessed at least once daily, depending on**

their individual needs.

**10.5.1. Is this part of your routine practice?** Yes, No, Don't know

**10.5.2. Importance rating.** 1,2,3,4,5

**10.6. Optimizing symptom control is part of the daily ward round goals**

**10.6.1. Is this part of your routine practice?** Yes, No, Don't know

**10.6.2. Importance rating.** 1,2,3,4,5

**10.7. Comments** (free text)

## **11. Psychosocial aspects of care**

**11.1. Various aspects of the patient's life are considered in their daily care**  
[For example: psychological (such as anxiety), Social, Spiritual, Existential, Financial]

**11.1.1. Is this part of your routine practice?** Yes, No, Don't know

**11.1.2. Importance rating.** 1,2,3,4,5

**11.2. The patient is encouraged to participate in daily activities when able**

**11.2.1. Is this part of your routine practice?** Yes, No, Don't know

**11.2.2. Importance rating.** 1,2,3,4,5

**11.3. The patient's treatment preferences are considered in their daily care**

**11.3.1. Is this part of your routine practice?** Yes, No, Don't know

**11.3.2. Importance rating.** 1,2,3,4,5

**11.4. Comments** (free text)

## **12. Communication and EoL care planning with the patient / family in ICU**

**12.1. Comprehensive and understandable information about the patient's diagnosis is provided.**

**12.1.1. Is this part of your routine practice?** Yes, No, Don't know

**12.1.2. Importance rating.** 1,2,3,4,5

**12.2. Comprehensive and understandable information about the patient's projected disease course is provided**

**12.2.1. Is this part of your routine practice?** Yes, No, Don't know

**12.2.2. Importance rating.** 1,2,3,4,5

**12.3. Comprehensive and understandable information about available treatment**

**options is provided**

**12.3.1. Is this part of your routine practice?** Yes, No, Don't know

**12.3.2. Importance rating.** 1,2,3,4,5

**12.4. Comprehensive and understandable information around of end-of-life care is provided**

**12.4.1. Is this part of your routine practice?** Yes, No, Don't know

**12.4.2. Importance rating.** 1,2,3,4,5

**12.5. The patient is involved in end-of-life decision-making (e.g. withholding/withdrawing life-sustaining treatments) when able.**

**12.5.1. Is this part of your routine practice?** Yes, No, Don't know

**12.5.2. Importance rating.** 1,2,3,4,5

**12.6. The family is involved in end-of-life decision-making (e.g. withholding/withdrawing life-sustaining treatments)**

**12.6.1. Is this part of your routine practice?** Yes, No, Don't know

**12.6.2. Importance rating.** 1,2,3,4,5

**12.7. Comments (free text)**

### **13. The role of and support for the family**

**13.1. The family's role in care is recognized and supported**

**13.1.1. Is this part of your routine practice?** Yes, No, Don't know

**13.1.2. Importance rating.** 1,2,3,4,5

**13.2. The family's expert knowledge of the patient and advocating for patient needs are valued**

**13.2.1. Is this part of your routine practice?** Yes, No, Don't know

**13.2.2. Importance rating.** 1,2,3,4,5

**13.3. The family is being supported to prepare for the patient's death; an opportunity to say goodbye is ensured if feasible.**

**13.3.1. Is this part of your routine practice?** Yes, No, Don't know

**13.3.2. Importance rating.** 1,2,3,4,5

**13.4. Care is extended to the family after the patient's death: family members are followed up after the patient's ICU death**

**13.4.1. Is this part of your routine practice?** Yes, No, Don't know

**13.4.2. Importance rating.** 1,2,3,4,5

**13.5. Comments** (free text)

**14. System-level multidisciplinary support**

**14.1. Is there effective cooperation among members of the treating team?** Yes, No, Don't know

**14.1.1. Importance rating.** 1,2,3,4,5

**14.2. Do you think that end-of-life decisions should include an interdisciplinary team of healthcare professionals?** Yes, No, Don't know

**14.2.1. Importance rating.** 1,2,3,4,5

**14.3. Do you think that end-of-life decisions should include the patient (if feasible)?** Yes, No, Don't know

**14.3.1. Importance rating.** 1,2,3,4,5

**14.4. Do you think that end-of-life decisions should include the family?** Yes, No, Don't know

**14.4.1. Importance rating.** 1,2,3,4,5

**14.5. Do you think that end-of-life decisions should include others?** Yes, No, Don't know

**14.5.1. If yes, please specify who?**

**14.5.2. Importance rating.** 1,2,3,4,5

**14.6. Comments** (free text)



## **Perceptions about legal framework for end of life/ treatment limitation decisions**

**Please use the following 5-point scale to rate the importance of the following elements of treatment limitation decisions; please note that "your country" = "the country in which you work"**

- 1=unimportant
- 2=low importance
- 3=average importance
- 4=high importance
- 5=maximum importance

**At the end of each domain, it is possible to clarify your responses and/or add other comments**

### **15. Regarding Do-not-attempt cardiopulmonary resuscitation (DNACPR) orders**

**15.1. Are they legally allowed in your country?** Yes, No, Don't know *(if no/Don't know – move on to question 16.1.)*

**15.2. Do you feel comfortable with existing legislation?** Yes, No, Don't know, Not applicable (NA)

**15.2.1. Importance rating.** 1,2,3,4,5

**15.3. Do you feel empowered to apply the existing legislation?** Yes, No, Don't know, NA

**15.3.1. Importance rating.** 1,2,3,4,5

**15.4. Do you feel empowered to document DNACPR?** Yes, No, Don't know, NA

**15.4.1. Importance rating.** 1,2,3,4,5

**15.5. Is the treating team involved in the decision for DNACPR** Yes, No, Don't know, NA

**15.5.1. Importance rating.** 1,2,3,4,5

**15.6. Is the patient involved in the decision for DNACPR (if feasible)?** Yes, No, Don't know, NA

**15.6.1. Importance rating.** 1,2,3,4,5

**15.7. Is the family involved in the decision for DNACPR?** Yes, No, Don't know, NA

**15.7.1. Importance rating.** 1,2,3,4,5

**15.8. Are other persons (e.g. religious leader) involved in the decision for DNACPR?**

Yes, No, Don't know, Not applicable (NA)

**15.8.1. If yes, please specify** (free text)

**15.8.2. Importance rating.** 1,2,3,4,5

**15.9. Comments** (free text)

## **16. Regarding advance directives**

**16.1. Do they exist in your country?** Yes, No, Don't know, Not applicable (NA) *(if no/Don't know/NA – move on to question 17.1.)*

**16.2. Are they legally binding in your country?** Yes, No, Don't know, NA

**16.3. Do you feel comfortable with existing legislation?** Yes, No, Don't know, NA

**16.3.1. Importance rating.** 1,2,3,4,5

**16.4. Do you feel empowered to apply them?** Yes, No, Don't know, NA

**16.4.1. Importance rating.** 1,2,3,4,5

**16.5. Do you feel empowered to document them?** Yes, No, Don't know, NA

**16.5.1. Importance rating.** 1,2,3,4,5

**16.6. Are they regularly reviewed (e.g. every 5 years)?** Yes, No, Don't know, NA

**16.6.1. Importance rating.** 1,2,3,4,5

**16.7. Comments** (free text)

## **17. Terminal analgesia / sedation**

(the use of analgesics and sedatives in dying patients until the point of death)

**17.1. Is it legally allowed in your country?** Yes, No, Don't know, Not applicable (NA)  
*(if no/Don't know/NA – move on to question 18.1.)*

**17.2. Do you feel comfortable with existing legislation?** Yes, No, Don't know, Not applicable (NA)

**17.2.1. Importance rating.** 1,2,3,4,5

**17.3. Do you feel empowered to apply it?** Yes, No, Don't know, NA

**17.3.1. Importance rating.** 1,2,3,4,5

**17.4. Do you feel empowered to document it?** Yes, No, Don't know, NA

**17.4.1. Importance rating.** 1,2,3,4,5

**17.5. Is the treating team involved in the decision for terminal sedation?** Yes, No, Don't know, NA

**17.5.1. Importance rating.** 1,2,3,4,5

**17.6. Is the patient involved in the decision for terminal sedation? (if feasible)?**

Yes, No, Don't know, NA

**17.6.1. Importance rating.** 1,2,3,4,5

**17.7. Is the family involved in the decision for terminal sedation?** Yes, No, Don't know, NA

**17.7.1. Importance rating.** 1,2,3,4,5

**17.8. Comments** (free text)

## **18. Withholding of treatment (i.e. avoiding escalation of an already administered treatment or avoiding to add a new treatment)**

**18.1. Is it legally allowed in your country?** Yes, No, Don't know, Not applicable (NA)  
(if no/Don't know/NA – move on to question 19.1.)

**18.2. Do you feel comfortable with existing legislation?** Yes, No, Don't know, Not applicable (NA)

**18.2.1. Importance rating.** 1,2,3,4,5

**18.3. Do you feel empowered to apply it?** Yes, No, Don't know, NA

**18.3.1. Importance rating.** 1,2,3,4,5

**18.4. Do you feel empowered to document it?** Yes, No, Don't know, NA

**18.4.1. Importance rating.** 1,2,3,4,5

**18.5. Does it include feeding?** Yes, No, Don't know, NA

**18.5.1. Importance rating.** 1,2,3,4,5

**18.6. Does it include hydration?** Yes, No, Don't know, NA

**18.6.1. Importance rating.** 1,2,3,4,5

**18.7. Comments** (free text)

## **19. Withdrawing of treatment (i.e. stopping/removing an already prescribed/ongoing treatment)**

**19.1. Is it legally allowed in your country?** Yes, No, Don't know, Not applicable (NA)

*(if no/Don't know/NA – move on to question 20.1.)*

**19.2. Do you feel comfortable with existing legislation?** Yes, No, Don't know, Not applicable (NA)

**19.2.1. Importance rating.** 1,2,3,4,5

**19.3. Do you feel empowered to apply it?** Yes, No, Don't know, NA

**19.3.1. Importance rating.** 1,2,3,4,5

**19.4. Do you feel empowered to document it?** Yes, No, Don't know, NA

**19.4.1. Importance rating.** 1,2,3,4,5

**19.5. Does it include feeding?** Yes, No, Don't know, NA

**19.5.1. Importance rating.** 1,2,3,4,5

**19.6. Does it include hydration?** Yes, No, Don't know, NA

**19.6.1. Importance rating.** 1,2,3,4,5

**19.7. Comments** (free text)

## **20. Euthanasia in adults**

**20.1. Is it legally allowed in your country?** Yes, No, Don't know, Not applicable (NA)

*(if no/Don't know/NA – move on to question 22.1.)*

**20.2. Do you feel comfortable with existing legislation?** Yes, No, Don't know, Not applicable (NA)

**20.2.1. Importance rating.** 1,2,3,4,5

**20.3. Do you feel empowered to apply it?** Yes, No, Don't know, NA

**20.3.1. Importance rating.** 1,2,3,4,5

**20.4. Do you feel empowered to document it?** Yes, No, Don't know, NA

**20.4.1. Importance rating.** 1,2,3,4,5

**20.5. Is the treating team involved in the euthanasia decisions?**

Yes, No, Don't know, NA

**20.5.1. Importance rating.** 1,2,3,4,5

**20.6. Comments** (free text)

## **21. Euthanasia in children**

**21.1. Is it legally allowed in your country?** Yes, No, Don't know, Not applicable (NA)

*(if no/Don't know/NA – move on to question 22.1.)*

**21.2. Do you feel comfortable with existing legislation?** Yes, No, Don't know, Not applicable (NA)

**21.2.1. Importance rating.** 1,2,3,4,5

**21.3. Do you feel empowered to apply it?** Yes, No, Don't know, NA

**21.3.1. Importance rating.** 1,2,3,4,5

**21.4. Do you feel empowered to document it?** Yes, No, Don't know, NA

**21.4.1. Importance rating.** 1,2,3,4,5

**21.5. Is the treating team involved in the euthanasia decisions?**

Yes, No, Don't know, NA

**21.5.1. Importance rating.** 1,2,3,4,5

**21.6. Comments** (free text)

## **22. Regarding EoL decisions**

**22.1. Do families participate in EoL decisions (adults)?** Yes, No, Don't know

**22.1. Importance rating.** 1,2,3,4,5

**22.2. Do families participate in EoL decisions (children)?** Yes, No, Don't know

**22.2.1. Importance rating.** 1,2,3,4,5

**22.3. For adults: Are EoL decisions reached through shared decision making?** Yes, No, Don't know

**22.3.1. Importance rating.** 1,2,3,4,5

**22.4. For children: Are EoL decisions reached through shared decision making?**

Yes, No, Don't know

**22.4.1. Importance rating.** 1,2,3,4,5

**22.5. Comments** (free text)

## **23. Family presence during Cardiopulmonary resuscitation (CPR)**

**23.1. For adults: is family presence allowed during CPR?** Yes, No, Don't know

**23.1.1. Importance rating.** 1,2,3,4,5

**23.2. For children: is family presence allowed during CPR?** Yes, No, Don't know

**23.2.1. Importance rating.** 1,2,3,4,5

**23.3. Comments** (free text)

**24. In your daily practice in ICU, do you have:****24.1. Intensive care unit (ICU) routine family meetings? Yes, No****24.2. ICU daily deliberation for appropriate level of ICU care? Yes, No****24.3. ICU end-of-life discussions during weekly meetings? Yes, No****24.4. ICU written triggers for limitations? Yes, No****24.5. ICU written end-of-life guidelines? Yes, No****24.6. ICU end-of-life protocols? Yes, No****24.7. ICU palliative care specialty consultations? Yes, No****24.8. ICU ethics consultations? Yes, No****24.9. ICU staff taking communication courses? Yes, No****24.10. ICU staff taking Bioethics Courses? Yes, No****24.11. Country end-of-life guidelines? Yes, No****24.12. Country end-of-life legislation? Yes, No****24.13. Any additional comments (free text)**

<b>EOL Practice Variable</b>	<b>Definition</b>
<b>Routine family meetings</b>	Regular (i.e. on admission and at least twice a week) scheduled conferences of at least one member of an ICU patient's family and at least one member of the treating team aimed at a) determining/clarifying the patient's health status, and comorbidities, b) patient values, preferences, and goals concerning treatment options; and c) conveying honest, accurate, and evidence-based information about patient clinical status and current/updated prognosis.
<b>Daily deliberation for appropriate level of care</b>	Routine daily discussions among members of the ICU treating team aimed at confirming that medical/surgical interventions administered to a patient are not disproportionate and/or do not contradict his/her preferences.
<b>EOL discussions during family meetings</b>	Conferences (on admission, and followed up at least as appropriate/feasible) of at least one member of an ICU patient's family and at least one member of the treating team aimed at determining and/or revising/adjusting EOL treatment goals according to the evolution of the patient's clinical course and (particularly changes) of prognosis, and "previously clarified" EOL values/preferences. This variable focuses on a specific type of family meetings' content aimed at achieving consistency between patient wishes and provided EOL care.
<b>Written ICU triggers for limitations</b>	A set of written, pre-specified medical and/or bioethical criteria for limiting LSTs in the ICU. Examples of such criteria may include: family request, presence of a pertinent living will that has to be respected, irreversible condition, un-survivable injury, severe brain injury with poor prognosis (e.g. minimally conscious state), high Sequential Organ Dysfunction Assessment Score plus poor response to acute illness treatment, multiple organ failure ( $\geq 3$ organs), non-beneficial therapy, and terminal illness.
<b>Written ICU EOL guidelines</b>	Written ICU recommendations (e.g. shared decision making, or obligation to inform the family about poor patient response to treatment, and/or lack of expected benefit from available and/or ongoing LSTs), with a written expectation to be followed for EOL decision-making and application of EOL decisions.
<b>Written ICU EOL (symptom management) protocols</b>	A written set of ICU recommendations and standards aimed at preventing any kind of patient distress (e.g. pain, dyspnea, delirium) during the application of LST limitation decisions on withholding and/or withdrawing of LSTs); written ICU EOL protocols may be based on recent, pertinent recommendations on how to perform withdrawing of LSTs.
<b>Palliative care consultations</b>	Consultations and/or liaison with specialists from the hospital's (specifically designated) palliative care service, focused on the treatment of symptoms (e.g. dyspnea, pain, or delirium), rather than the treatment of any underlying disease processes. Psychosocial and spiritual needs may also be attended to in patients who do not require sedation and are able to communicate. Such consultations may take place whenever LST limitation is considered, in the context of communication of available treatment options to the patient/family. An exception to the former requirement pertains to the presence of an intensivist with palliative care expertise in the ICU treating team.
<b>Ethics consultations</b>	Consultations and/or liaison with a specialist from the hospital's (specifically designated) clinical ethics committee, focused on addressing of any ensuing ethical dilemmas and/or challenges, including disagreements (that cannot otherwise be resolved) between surrogate decision-makers, between the patient/family and the ICU treating team, health care professionals or others.

<b>EOL Practice Variable</b>	<b>Definition</b>
<b>Communication courses</b>	Lessons focused at developing or improving the capability of 1) expressing oneself clearly, honestly, and accurately (about available treatment options), and also in a way that is readily understood by the patient/family; and 2) providing psychological support, and showing empathy to the patient/family.
<b>Bioethics courses</b>	Lessons focused on improving the knowledge, understanding of the widely accepted four Principles of Bioethics, and/or the capability of effectively addressing ethical dilemmas and challenges of routine clinical practice.
<b>Country EOL guidelines</b>	Written recommendations by national medical societies, or statutory governing bodies, for EOL decision making and EOL practices (e.g. symptom control and/or procedure for withdrawal of mechanical ventilation) in the ICU.
<b>Country EOL legislation</b>	A set of laws aimed at addressing commonly ensuing ethical issues as part of routine clinical practice (e.g. Should advance directives always be followed? Are withholding or withdrawing of LSTs, or active shortening of the dying process legally allowed?, etc.).
<b>EOL practice score</b>	The sum of binary (i.e. 0 or 1) grading of the 12 EOL practice variables according to their absence (=0) or presence (=1); score range: 0-12.

**25.1. Do you believe that there is adequate focus on palliative care needs in your ICU?**

Yes, to a very high degree  
 Yes, to a high degree  
 Yes, to some degree  
 Yes, but to a low degree  
 No, not at all  
 Do not know

**25.2. In your opinion, what facilitates provision of palliative care in your ICU?**  
 (free text comments)

**25.3. In your opinion, what are the barriers to the provision of palliative care in your ICU?**  
 (free text comments)

**25.4. Other comments regarding palliative care in ICU?** (free text comments)



**Thank you very much for your help**